Health Canada approves Inflectra (biosimilar infliximab) for three additional indications
The addition of Crohn's disease, fistulising Crohn's disease and ulcerative colitis to the approved indications was granted on the basis of similarity between Inflectra and the reference product, Remicade.
Hospira, a Pfizer company, has announced that Inflectra (biosimilar infliximab) has been approved by Health Canada for three additional indications, Crohn's disease (CD), fistulising Crohn's disease and ulcerative colitis (UC).
Inflectra is Canada's first biosimilar monoclonal antibody (mAb) therapy, and was approved by Health Canada in 2014 for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The addition of CD, fistulising CD and UC to the approved indications was granted on the basis of similarity between Inflectra and the reference product, Remicade, in product quality, mechanism of action, disease pathophysiology, safety profile, dosage regimen and on clinical experience with the reference product.
While relatively new to the Canadian market, biosimilars have been approved for use in Europe for more than 10 years. Pfizer has significant experience with Inflectra, and accordingly, have accumulated real world data across indications - inclusive of CD and UC.
Pfizer believes biosimilars are poised to play a key role in creating a more sustainable health care system in Canada, by helping address the evolving needs of patients, physicians, government payers and private insurers. The adoption of biosimilars has the potential to expand patient access to these important medicines and to provide additional treatment options for patients living with life-threatening and chronic diseases.
Following the pan-Canadian Pharmaceutical Alliance (pCPA) process, Inflectra is now available on public formularies across Canada, for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis. In most provinces, Inflectra is the preferred infliximab option.
In addition, Inflectra has been listed on the large majority of private insurance formularies in Canada. Inflectra also offers a comprehensive patient assistance program.
Pfizer will now work with provincial drug programs, private payers and other stakeholders to ensure CD and UC are part of the indications approved for reimbursement.
"The Health Canada approval of these three additional indications for Inflectra is an important development for patients. We've already reached a significant milestone having successfully completed discussions with the pCPA earlier this year, and, as a result, Inflectra is the preferred infliximab option in most provinces. We look forward to our continued work with individual provinces and private insurers to support the implementation of Inflectra reimbursement," said Gerry Stefanatos, General Manager, Global Established Pharma Business, Pfizer Canada.
"Biosimilars such as Inflectra will be a key element to sustain affordable health care, especially here in Canada. Biosimilars have the potential to offer a significantly lower cost compared to the original biologic medicines. The benefits in cost saving to health care systems could be significant," said Dr Brian Bressler, Gastroenterologist, Clinical Associate Professor of Medicine, Division of Gastroenterology, University of British Columbia.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance